1492 related articles for article (PubMed ID: 36451813)
1. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma.
Liu C; Liu D; Wang F; Liu Y; Xie J; Xie J; Xie Y
Front Immunol; 2022; 13():1038927. PubMed ID: 36451813
[TBL] [Abstract][Full Text] [Related]
2. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
[TBL] [Abstract][Full Text] [Related]
3. Identification of a glycolysis- and lactate-related gene signature for predicting prognosis, immune microenvironment, and drug candidates in colon adenocarcinoma.
Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Peng J; Xie Y
Front Cell Dev Biol; 2022; 10():971992. PubMed ID: 36081904
[No Abstract] [Full Text] [Related]
4. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
[TBL] [Abstract][Full Text] [Related]
5. The Interferon Gamma-Related Long Noncoding RNA Signature Predicts Prognosis and Indicates Immune Microenvironment Infiltration in Colon Adenocarcinoma.
Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Xie Y
Front Oncol; 2022; 12():876660. PubMed ID: 35747790
[TBL] [Abstract][Full Text] [Related]
6. Developing a prognosis and chemotherapy evaluating model for colon adenocarcinoma based on mitotic catastrophe-related genes.
Liu Y; Zhao Y; Zhang S; Rong S; He S; Hua L; Wang X; Chen H
Sci Rep; 2024 Jan; 14(1):1655. PubMed ID: 38238555
[TBL] [Abstract][Full Text] [Related]
7. Lactate Metabolism-Associated lncRNA Pairs: A Prognostic Signature to Reveal the Immunological Landscape and Mediate Therapeutic Response in Patients With Colon Adenocarcinoma.
Xiao J; Wang X; Liu Y; Liu X; Yi J; Hu J
Front Immunol; 2022; 13():881359. PubMed ID: 35911752
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance and immune landscape of a fatty acid metabolism-related gene signature in colon adenocarcinoma.
Liu X; Fang X; Lu L; Liu G
Front Genet; 2022; 13():996625. PubMed ID: 36568396
[No Abstract] [Full Text] [Related]
9. A novel signature model based on mitochondrial-related genes for predicting survival of colon adenocarcinoma.
Gao H; Xing F
BMC Med Inform Decis Mak; 2022 Oct; 22(1):277. PubMed ID: 36273131
[TBL] [Abstract][Full Text] [Related]
10. Exploration of the relationship between tumor mutation burden and immune infiltrates in colon adenocarcinoma.
Ouyang R; Li Z; Peng P; Zhang J; Liu J; Qin M; Huang J
Int J Med Sci; 2021; 18(3):685-694. PubMed ID: 33437203
[No Abstract] [Full Text] [Related]
11. Transcriptomic correlates of cell cycle checkpoints with distinct prognosis, molecular characteristics, immunological regulation, and therapeutic response in colorectal adenocarcinoma.
Wang H; Wang W; Wang Z; Li X
Front Immunol; 2023; 14():1291859. PubMed ID: 38143740
[TBL] [Abstract][Full Text] [Related]
12. Identification of a Four-Gene Metabolic Signature to Evaluate the Prognosis of Colon Adenocarcinoma Patients.
Zheng Y; Wu R; Wang X; Yin C
Front Public Health; 2022; 10():860381. PubMed ID: 35462848
[TBL] [Abstract][Full Text] [Related]
13. Identification of the six-hormone secretion-related gene signature as a prognostic biomarker for colon adenocarcinoma.
Jia X; Zhang T; Lv X; Du H; Sun Y; Guan Y
Cancer Biomark; 2023; 38(4):523-535. PubMed ID: 38143338
[TBL] [Abstract][Full Text] [Related]
14. A novel enterocyte-related 4-gene signature for predicting prognosis in colon adenocarcinoma.
Cheng X; Wei Y; Fu Y; Li J; Han L
Front Immunol; 2022; 13():1052182. PubMed ID: 36532007
[TBL] [Abstract][Full Text] [Related]
15. Glucose metabolism-based signature predicts prognosis and immunotherapy strategies for colon adenocarcinoma.
Bai Z; Yan C; Nie Y; Zeng Q; Xu L; Wang S; Chang D
J Gene Med; 2024 Jan; 26(1):e3620. PubMed ID: 37973153
[TBL] [Abstract][Full Text] [Related]
16. Predictive Models for Colon Adenocarcinoma Diagnosis, Prognosis, and Immune Microenvironment Based on 2 Hypoxia-Related Genes: KDM3A and ENO3.
Kong C; Zheng L; Fang S; Chen M; Lin G; Qiu R; Zhao Z; Chen W; Song J; Yang Y; Ji J
Technol Cancer Res Treat; 2023; 22():15330338231195494. PubMed ID: 37650153
[No Abstract] [Full Text] [Related]
17. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma.
Xu M; Mu J; Wang J; Zhou Q; Wang J
Front Oncol; 2022; 12():961213. PubMed ID: 35965536
[TBL] [Abstract][Full Text] [Related]
18. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
19. Identification of DLL3-related genes affecting the prognosis of patients with colon adenocarcinoma.
Xiang J; Gong W; Liu J; Zhang H; Li M; Wang R; Lv Y; Sun P
Front Genet; 2023; 14():1098190. PubMed ID: 37274780
[No Abstract] [Full Text] [Related]
20. Metabolism-Related Prognostic Biomarkers, Purine Metabolism and Anti-Tumor Immunity in Colon Adenocarcinoma.
Liu H; Zhang Y; Zhang Q; Zhang T; Lu T
Front Biosci (Landmark Ed); 2023 Dec; 28(12):328. PubMed ID: 38179743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
